The significance of androgen receptor (AR) in breast cancer (BC) management is not fully defined, and it is still ambiguous how the level of AR expression influences oestrogen receptor-positive (ER+) tumours. The aim of the present study was to analyse the prognostic impact of AR/ER ratio, evaluated by immunohistochemistry (IHC), correlating this value with clinical, pathological and molecular characteristics. We retrospectively selected a cohort of 402 ER+BC patients. On each tumour, IHC analyses for AR, ER, PgR, HER2 and Ki67 were performed and AR+ cases were used to calculate the AR/ER value. A cut-off of ≥2 was selected using receiver-operating characteristic (ROC) curve analyses. RNA from 19 cases with AR/ER≥2 was extracted and used for Prosigna-PAM50 assays. Tumours with AR/ER≥2 (6%) showed more frequent metastatic lymph nodes, larger size, higher histological grade and lower PgR levels than cases with AR/ER<2. Multivariate analysis confirmed that patients with AR/ER≥2 had worse disease-free interval (DFI) and disease-specific survival (DSS) (hazard ratios (HR) = 4.96 for DFI and HR = 8.69 for DSS, both P ≤ 0.004). According to the Prosigna-PAM50 assay, 63% (12/19) of these cases resulted in intermediate or high risk of recurrence categories. Additionally, although all samples were positive for ER assessed by IHC, the molecular test assigned 47.4% (9/19) of BCs to intrinsic non-luminal subtypes. In conclusion, the AR/ER ratio ≥2 identifies a subgroup of patients with aggressive biological features and may represent an additional independent marker of worse BC prognosis. Moreover, the Prosigna-PAM50 results indicate that a significant number of cases with AR/ER≥2 could be non-luminal tumours.
Introduction
Oestrogen receptor (ER) and progesterone receptor (PgR) are expressed in most breast cancers (BCs) (~75%) and both have wide prognostic and predictive utility (Early Breast Cancer Trialists' Collaborative Group 2011) . In contrast, the clinical and biological significance of androgen receptor (AR) expression in BC is not fully defined. AR positivity has been detected in up to 61% of primary and metastatic BC lesions (Park et al. 2010 , Hu et al. 2011 , Yu et al. 2011 and approximately 75% of ER-positive (ER+) BCs are also AR positive (AR+). Several studies have shown that AR expression in luminal tumours (ER+) is associated with lower tumour grade, smaller tumour size, lower proliferative index (Ki67 level) and more importantly, AR expression in ER+ tumours is an independent prognostic factor of a good outcome (Castellano et al. 2010 , Niemeier et al. 2010 , Aleskandarany et al. 2016 , Bozovic-Spasojevic et al. 2016 . On the other hand, up to 31% of ER-negative (ER−) BCs are reported to be AR+ (Niemeier et al. 2010 , Park et al. 2010 , but the prognostic impact of AR expression in this subset of BCs is not clear (Luo et al. 2010 , Hu et al. 2011 , Park et al. 2011 , Pistelli et al. 2014 , Vera-Badillo et al. 2014 , Hilborn et al. 2016 , Jiang et al. 2016 , Asano et al. 2017 .
While the interaction between the signalling pathways of ER and AR (Peters et al. 2009 ) is well known, it is still ambiguous how the level of AR expression influences ER+ tumours. In vitro studies have shown that AR signalling inhibits oestrogen-induced proliferation of ER+ MCF7 BC cells (Ando et al. 2002 , Greeve et al. 2004 , Macedo et al. 2006 , Cops et al. 2008 ). This inhibitory effect seems to be mediated by several mechanisms, but the most important is the ability of AR to compete with ER for binding of oestrogen response elements (EREs), preventing ER-dependent gene transcription (Need et al. 2012) . In line with this observation, some studies have reported that increasing AR expression results in a greater androgen-dependent inhibition of ER function (Buchanan et al. 2005 , Peters et al. 2009 ). However, other studies performed on ER+ MCF7 BC cells described an increase in proliferation when the AR signalling pathway is stimulated (Birrell et al. 1995 , Lin et al. 2009 ). Moreover, Cochrane and coworkers (Cochrane et al. 2014) recently reported that high AR levels and low ER levels (higher AR/ER ratio) could be associated with a worse prognosis and tamoxifen (TAM) resistance.
Considering these data, the aim of the present study was to analyse the prognostic impact of AR expression with respect to ER (AR/ER ratio) in a large case series of ER+/HER2-negative (HER2−) BC patients. We evaluated if the AR/ER ratio may identify a subset of tumours with different clinical and pathological characteristics. In addition, in the subgroup of BCs with high AR/ER ratio values, we performed Prosigna-PAM50 assays to assess the molecular subtypes of these BCs.
Patients and methods

Study design and population
We collected a cohort of 402 ER+/HER2− primary invasive BC patients with available follow-up (Fig. 1) , who underwent surgery from January 1998 to December 2012 at the Breast Unit of the Città della Salute e della Scienza of Torino, University Hospital of Torino in Turin, Italy. In the diagnostic setting, the cut-off value considered for ER and PgR positivity was ≥1%, as suggested by the St Gallen and ASCO/CAP Guideline Recommendations (Hammond et al. 2010 , Coates et al. 2015 , and the same cut-off was adopted for AR positivity (Castellano et al. 2010) . For all cases, the following clinico-pathological data were obtained from the clinical charts and pathological reports: age, type of surgery (conservative surgery vs radical mastectomy), tumour size (<15 mm vs ≥15 mm), histological type, tumour grade and nodal involvement. Ethical approval for this study was obtained from the Comittee for human Biospecimen Utilization (Department of Medical Sciences -ChBU). The project provided an informed consent, obtained from the patients at the time of surgery due to the retrospective approach of the study, which did not impact on their treatment. The procedure for collecting the consent was approved by the Committee for human Biospecimen Utilization (Department of Medical Sciences -ChBU). All the cases were anonymously recorded, and data were accessed anonymously. Study flowchart. ER -estrogen receptor; HER2 -human epidermal growth factor receptor 2; AR -androgen receptor. *Three additional cases (without follow-up) with a ratio of AR/ER≥2 were included for the Prosigna-PAM50 assay.
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Immunohistochemistry (IHC)
For each case, representative blocks were selected and multicore tissue microarrays (TMAs) were prepared, as previously described (Sapino et al. 2006) . (Coates et al. 2015) , we adopted a cut-off of 20% for dichotomizing tumours as having low and high levels of PgR and Ki67. In addition, this cut-off agrees with the median Ki67 value of our laboratory, previously established to differentiate tumours with a higher proliferative index (Coates et al. 2015 , Bustreo et al. 2016 .
AR/ER ratio calculation
AR and ER nuclear staining percentages were compared. Post estimation ROC curve after logistic regression was used to establish the optimal AR/ER ratio cut-off value, which allowed us to subdivide the patients into those with good and worse prognosis as described below.
Statistical analyses
Pearson's chi-square test and Student's t-test were preliminarily performed to compare categorical and continuous variables, respectively, and to evaluate the potential differences in the variable distribution among the groups. The disease-free interval (DFI) was calculated from the date of surgical excision of the primary tumour to the date of the first relapse or last check-up. Diseasespecific survival (DSS) was calculated from the surgical excision date of the primary tumour to the date of BC death or last check-up. Survival distribution curves were plotted using the Kaplan-Meier method and the statistical comparisons were performed using the log-rank test. Cox regression analyses were carried out on the DFI and DSS to calculate the crude and adjusted HR and 95% CIs for the different study group. The cases lost to follow-up and cases with non-breast cancer-related deaths were censored at the last follow-up. Models were created to evaluate the prognostic role of different variables. The proportional hazard assumption was assessed with the Schoenfeld residuals. This did not give reasons to suspect a violation of this assumption. The nature of the variables Figure 2 Immunohistochemical staining. Representative IHC for the androgen receptor (A and C) and estrogen receptor (B and D) in two BC cases with high AR levels with respect to ER (AR/ER≥2). Although ER is expressed at the IHC level in these cases, the molecular test classified them as non-luminal subtypes. 
Prosigna multigene prognostic assay
Sixteen ER+/HER2− BC cases with an AR/ER ratio ≥2 with long follow-up and 3 additional cases collected during the routine diagnostic assessment of ER and AR were selected for Prosigna-PAM50 analysis (NanoString Technologies, Seattle, WA, USA). Briefly, tissue obtained after macrodissection of formalin-fixed paraffin-embedded (FFPE) tumours were processed with a Roche FFPET RNA Isolation Kit (Roche). The isolated RNA was hybridized to 58 gene-specific probe pairs, plus 6 positive and 8 negative controls (Capture and Reporter Probes -Prosigna CodeSet. NanoString Technologies), overnight at 65°C in a single hybridization reaction. The removal of excess probes, followed by binding of the probe-target complexes on the surface of a specific nCounter cartridge, was performed on the nCounter Prep Station (NanoString Technologies). Finally, the nCounter cartridge with immobilized probe/ target complexes was read in the nCounter Digital Analyzer (NanoString Technologies). The conversion of gene expression measurements into intrinsic molecular subtypes, risk of recurrence (ROR) scores and risk categories used a fully prespecified algorithm has been previously described (Parker et al. 2009 , Dowsett et al. 2013 .
Results
Patients and tumour characteristics
Clinical and pathological features of the 402 ER+/ HER2− tumours according to the AR status are shown in Supplementary Table 1 (see section on supplementary data given at the end of this article). The median time of follow-up was 8 years. The majority of cases, 70.6% (284/402), were AR+. The distribution plots of IHC ER and AR nuclear staining percentages are presented in Supplementary Fig. 1 . According to our previous reports (Castellano et al. 2010 (Castellano et al. , 2013 , we confirmed that AR expression (≥1% nuclear staining) was significantly correlated with a longer DSS (P = 0,0008; Supplementary  Fig. 2 ) of ER+ BC patients.
AR/ER ratio and correlation with histological and immunohistochemical features
The median AR/ER ratio was 0.51. Two was the optimal AR/ER ratio that differentiated the cohort by prognosis (AR/ER≥2: AUC = 0.74; P = 0.002) (Supplementary Fig. 3 ). The characteristics of the 284 ER+/HER2−/AR+ BC cases stratified by an AR/ER ratio cut-off are reported in Table 1 . Of the 284 AR+/ER+ cases, 268 (94%) had an AR/ER ratio <2 and 16 (6%) an AR/ER ratio ≥2 (Fig. 1 and Fig. 2 ). In the descriptive analysis, patients with a higher AR/ER ratio carried larger tumours with a higher histological grade and lower PgR levels, and they frequently had more metastatic lymph nodes and had a higher number of relapse events (P ≤ 0.004) ( Table 1 ).
Figure 3 Survival curves for AR/ER<2 vs AR/ER≥2. (A) Disease-free interval (DFI).
(B) Disease-specific survival (DSS). *Log-rank test for equality of survivor functions.
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AR/ER ratio and impact on prognosis
As shown in Table 2 , univariate analysis confirmed that an AR/ER ratio ≥2 was one of the most significant markers of poor survival (HR = 7.55 for DFI, and HR = 10.84 for DSS, both P < 0.001), together with tumour grade, tumour size ≥15 mm, nodal involvement ≥4 and high Ki67 index. Moreover, the Kaplan-Meier curves and the logrank test showed significant differences in the survival times between the two groups (DFI and DSS P < 0.001) ( Fig. 3A and B) . In the analysis, we also included ER and AR expression as continuous variables to compare the weight on the prognosis of different levels of the receptor expression with the AR/ER ratio. While the percentage of AR expression did not show any impact on prognosis, the levels of ER were correlated with prognosis although at a lower significance compared to the AR/ER ratio (Table 2) . Multivariate analysis confirmed an independent effect on the prognosis of the AR/ER ratio. According to this model, patients with an AR/ER≥2 were five times more likely to relapse (HR = 4.96, P < 0.001 for DFI) and eight times more likely to die of BC (HR = 8.69, P = 0.004 for DSS) compared with patients with a ratio <2. Tumour size ≥15 mm, lymph nodes >9 and a high Ki67 index had an unfavourable effect on DFI and DSS (Table 3 ). The proportionality assumption was satisfied both for the DFI (P = 0.1227) and DSS (P = 0.3517).
To exclude the possibility that prognostic information from the AR/ER ratio was only a consequence of the low ER levels, we additionally tested a cut-off point for ER nuclear staining at 10%. As expected, patients with lower ER levels (<10%) were associated with worse DFI and DSS ( Supplementary Fig. 4 ). However, according to the AIC test, which was used for model selection, the AR/ER ratio model received the lowest AIC score (DFI AIC = 378.8, DSS AIC = 139.7), indicating that this model is more effective at providing prognostic information than the model with an ER cut-off at 10% (DFI AIC = 384.6, DSS AIC = 145.9). Furthermore, although patients with lower ER levels were more likely to have AR/ER≥2, 56.2% of tumours (9/16 cases) with a high AR/ER ratio had a high ER level (≥10%).
AR/ER≥2 and association with intrinsic molecular subtypes
A Prosigna-PAM50 assay was performed on the 19 cases with a ratio AR/ER≥2 to evaluate their ROR and molecular subtype. Twelve out of the 19 cases (63.2%) resulted in intermediate or high-risk categories (high probability of distant recurrence at 10 years) ( Table 4) . We then compared the IHC-based subtypes (Hammond et al. 2010 , Coates et al. 2015 with the intrinsic molecular subtype obtained by the Prosigna-PAM50 assay and the percentage of ER expression. Three cases were classified as IHC luminal A (15.8%) and 16 cases as luminal B (84.2%). The concordance between the IHC subtypes and intrinsic molecular subtypes was very low (k = 0.0583) since only 2 cases (10.5%) maintained the same subtype (luminal A) using the Prosigna-PAM50 assay. Molecular tests classified 47.4% of samples as luminal A, 5.3% as luminal B, 10.5% as HER2-enriched and 36.8% as a basal-like subtype ( Fig. 4A and Table 4 ). Thus, gene expression analysis showed that 47.4% of BCs with an AR/ER ratio ≥2 were assigned to non-luminal subtypes (Fig. 2, Fig. 4A and Table 4 ). The correlation with the percentage of ER expression showed that 6 of the cases that switched from luminal to non-luminal had an ER<10%, although two cases classified as luminal A by Prosigna-PAM50 assay had an ER<10% (2% and 5%, respectively) (Fig. 4B ).
Discussion
In our study, we demonstrated that within ER+ BCs, the AR/ER ratio may represent an additional independent prognostic marker. Specifically, we showed that BCs with an AR/ER ratio ≥2 had a worse DFF and DSS. This particular subset of tumours is rare within ER+ BCs and, from the molecular point of view, they do not always fit with the luminal subtype.
The prognostic role of AR in ER+ BC has been extensively studied. Several authors have reported that AR expression in luminal cancers is associated with a better outcome compared to AR negative BCs (Park et al. 2011 , Castellano et al. 2013 , Kim et al. 2015 , BozovicSpasojevic et al. 2016 . However, some reports suggest that AR could be related to BC progression (Grogg et al. 2015) , as it is detected in a significantly higher percentage of ductal carcinomas 'in situ' (DCIS) that are adjacent to invasive carcinomas than in pure DCIS (Yu et al. 2011) . Moreover, although the expression of ER and PgR decrease during BC progression (from DCIS to invasive and from G1 to G3), AR expression is highly conserved during BC progression, as it is detected in a high percentage of metastatic tumours (Cimino-Mathews et al. 2012 , Grogg et al. 2015 . In addition, Gonzalez and coworkers (Gonzalez et al. 2008) found that AR+ tumours are frequently positive for matrix metalloproteinases (MMPs), which have been involved in breast tumour dissemination. Finally, a recent study indicated that AR expression can induce the epithelial-to-mesenchymal transition in ER+ BC cells, conferring them with metastatic potential (Feng et al. 2016) .
Panet-Raymond and coworkers (Panet-Raymond et al. 2000) reported that co-expression of both ER and AR reduces the trans-activation function of AR, and Takagi and coworkers (Takagi et al. 2010) suggested that AR signalling is suppressed in BC by high ER signalling activity.
All these results indicate that the interaction between the ER and AR levels may influence the AR activity. In line with this hypothesis, we found that BCs with a high AR/ER ratio are associated with aggressive biological features and worse prognosis.
To the best of our knowledge, only Cochrane and coworkers reported an association between AR/ER ratio and outcome (Cochrane et al. 2014) . They showed that AR/ER ratio ≥2 is a good predictor of DFI and DSS, in a cohort of ER+ BC patients. AR/ER optimal ratio (AR/ER≥2) was further defined and confirmed to predict DFI and DSS in our cohort (ER+/HER2− BC patients) by univariate Cox (HR) analysis. However, they reported a higher percentage of cases with an AR/ER ratio ≥2 than in our series (11.4% vs 6% respectively), which is probably related to differences in case selection since we excluded tumours with HER2 positivity.
The molecular analysis with Prosigna-PAM50 confirmed that most cases with AR/ER≥2 had a high-tointermediate ROR. In addition, Prosigna-PAM50 assay assigned 47.4% of our IHC luminal cases to the nonluminal intrinsic molecular subtypes. These results could suggest that tumours with a high AR/ER ratio could be resistant to hormone therapy. In fact, in vitro studies have demonstrated that hormone therapy-resistant tumours express higher levels of AR and lower ER levels than hormone therapy-sensitive tumours (De Amicis et al. 2010 , Fujii et al. 2014 , Rechoum et al. 2014 , Ciupek et al. 2015 . To confirm these experimental data, Cochrane and coworkers demonstrated that AR/ER≥2 was associated with an increased risk of tamoxifen therapy failure in BC patients (Cochrane et al. 2014) . Taken together, these data may suggest that BCs with an AR/ER≥2 could represent tumours that are changing or evolving from ER dependence (luminal subtype) to AR dependence, with the progressive loss of ER expression (non-luminal subtype).
Our study has some limitations due to its retrospective design. We included in the analysis patients with different treatment (hormone therapy and chemotherapy), and we do not have validation setting of patients to confirm our data. To address these limitations and validate our data, future studies need to include larger cohort of patients, who possibly underwent the same therapeutic approach.
In conclusion, our results suggest that tumours with AR/ER≥2 should be carefully evaluated and reinforce the idea of targeting AR for BC treatment.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/ ERC-17-0417.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. 
